Survival Unaffected From Addition of Ramucirumab or Merestinib to Standard First-Line Chemotherapy for Metastatic Biliary Tract CancerNovember 1st 2021
Patients with locally advanced or metastatic biliary tract cancer who received either ramucirumab or merestinib in addition to standard first-line cisplatin and gemcitabine did not experience further survival benefit, although safety remained tolerable.
EBRT Underutilized as Bridging Therapy to Transplant for Hepatocellular Carcinoma Although Use Increased Over Past DecadeOctober 26th 2021
A retrospective review found that external-beam radiation therapy has been underutilized as a bridging therapy in patients with hepatocellular carcinoma seeking transplant, although its prevalence has increased over the past decade.
Durvalumab Plus Tremelimumab Combo Provides Significant Survival Benefit in First-Line Unresectable Hepatocellular CarcinomaOctober 15th 2021
Patients with unresectable hepatocellular carcinoma appeared to benefit from treatment with durvalumab and tremelimumab, according to findings from the phase 3 HIMALAYA trial.
Tremelimumab/Durvalumab Combo Safe and Efficacious for Unresectable Hepatocellular CarcinomaOctober 8th 2021
Tremelimumab plus durvalumab demonstrated encouraging safety and efficacy data compared with single agent durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma.
Promising Responses Observed in HER2+, Metastatic Biliary Tract Cancer Following Treatment With Pertuzumab and TrastuzumabSeptember 15th 2021
Patients with HER2-positive, metastatic biliary tract cancer experienced promising responses and a tolerable safety profile following treatment with pertuzumab plus trastuzumab.
NovoTTF-200T Delivery System Given a Breakthrough Designation by the FDA for Advanced Liver CancerSeptember 10th 2021
The NovoTTF-200T System was given a breakthrough designation by the FDA as treatment strategy that may work in conjunction with bevacizumab and atezolizumab to treat patients with advanced liver cancer.
Precision1 Trial May Allow for Precision Medicine in Liver Cancer by Integrating MRI With Whole Genome SequencingAugust 18th 2021
The prospective observational Precision1 cohort study will integrate imaging technology with actionable whole genome sequencing in patients with primary and secondary liver cancer.
Sintilimab Plus Bevacizumab Biosimilar IBI305 Demonstrates OS and PFS Benefit Over Sorafenib in HCCJuly 23rd 2021
Patients with unresectable hepatitis B virus–positive hepatocellular carcinoma have achieved significantly better overall survival and progression-free survival following treatment with sintilimab plus IBI305 vs sorafenib.